Effects of adalimumab and secukinumab on comorbidities associated with metabolism in patients with plaque psoriasis

[...]a significant difference in the prevalence of low–high-density lipoprotein cholesterol (HDL-C) was observed between psoriasis and control groups (18.5% and 9.9%, P = 0.017). Furthermore, adalimumab had no significant effect on body mass index (BMI), blood glucose, and blood pressure of patients...

Full description

Saved in:
Bibliographic Details
Published in:Chinese medical journal 2022-09, Vol.135 (18), p.2248-2250
Main Authors: Zhang, Si, Cai, Lin, Zhang, Heng, Zhao, Zheng, Liu, Xiaoyang, Zhao, Yan, Zhang, Jianzhong
Format: Article
Language:English
Subjects:
Adalimumab - therapeutic use
Antibodies, Monoclonal, Humanized - therapeutic use
Biochemistry
Biological products
Blood pressure
Body mass index
Cholesterol
Correspondence
Diabetes
Gastrointestinal surgery
Glucose
High density lipoprotein
Humans
Hyperglycemia
Hypertension
Lipoproteins
Metabolic disorders
Metabolic syndrome
Missing data
Obesity
Overweight
Population
Psoriasis
Psoriasis - drug therapy
Severity of Illness Index
Treatment Outcome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:[...]a significant difference in the prevalence of low–high-density lipoprotein cholesterol (HDL-C) was observed between psoriasis and control groups (18.5% and 9.9%, P = 0.017). Furthermore, adalimumab had no significant effect on body mass index (BMI), blood glucose, and blood pressure of patients with psoriasis [Table 1]. Secukinumab had no significant effect on BMI, blood glucose, and blood pressure of patients with psoriasis [Table 1].Table 1 Clinical characteristics before and after treatment with adalimumab and Secukinumab. Last observation carried forward; LDL-C: Low-density lipoprotein cholesterol; M/F: Male : Female; MS:
ISSN:0366-6999
2542-5641
DOI:10.1097/CM9.0000000000002143